Novartis R&D expenditure 2004-2023

This statistic shows the expenditure on research and development of Swiss-based pharmaceutical company Novartis from 2004 to 2023. Novartis AG is one of the world's largest pharma companies. In 2023, Novartis spent approximately 11.4 billion U.S. dollars on research and development.

Novartis AG's expenditure on research and development from 2004 to 2023 (in billion U.S. dollars)

Characteristic	Expenditure in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

January 2024

More information

Region

Worldwide

Survey time period

2004 to 2023

Supplementary notes

This statistic was assembled from several annual reports.
* With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015.
** During 2019, eye care division Alcon was spun off and became an own company. Thus, Alcon's expenses are not included.
** During 2023, generics division Sandoz was spun off and became an own company. Thus, Sandoz's expenses are not included.

Open this statistic in...

French

Citation formats